#Merck and #Eisai Receive Complete Response Letter for #KEYTRUDA® (#Pembrolizumab) plus #LENVIMA® (#Lenvatinib) Combination as First-Line Treatment for Unresectable #HepatocellularCarcinoma $MRK https://t.co/dox8IlpR3D